SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SPDR S&P 500 ETF TRUST - Units of undivided interest in SPDR Trust Series 1

The S&P 500 ETF is experiencing intense volatility and aggressive price swings as the market reacts to speculative headlines regarding geopolitical tensions and potential protocols for shipping routes. The community is deeply polarized, with many retail traders accusing large institutions of orchestrating 'fake' rallies to trap bears and manipulate options liquidity before a long holiday weekend.

Intuitive Machines, Inc. is a space exploration, infrastructure, and services company, which engages in contributing to the establishment of cislunar infrastructure and helping to develop cislunar and deep space commerce. It offers space products and services. The company was founded by Stephen J. Altemus, Kam Ghaffarian, and Timothy P. Crain in 2013 and is headquartered in Houston, TX.

Intuitive Machines Inc - Ordinary Shares - Class A

Intuitive Machines Inc

Intuitive Machines is surging as the community celebrates the successful Artemis II launch and anticipates the company's pivotal role in lunar infrastructure. Investors are actively discussing a potential short squeeze fueled by high volume and institutional interest, while debating the impact of upcoming NASA contract awards and the broader momentum in the space sector.

Invesco QQQ Trust Series 1 - Units of beneficial interest

QQQ is experiencing heightened volatility and intense social media debate, driven by uncertainty surrounding geopolitical developments in the Middle East and the market's reaction to recent presidential commentary. The community remains deeply divided, with significant arguments playing out between bulls anticipating a classic dip-buy and bears pointing toward escalating oil prices and macroeconomic concerns as catalysts for a broader sell-off.

Lumentum Holdings, Inc. engages in the provision of optical and photonic products. It operates through the Cloud and Networking, and Industrial Tech segments. The Cloud and Networking segment refers to a portfolio of optical and photonic components, modules, and subsystems. The Industrial Tech segment includes solid-state lasers, kilowatt-class fiber lasers, ultrafast lasers, diode lasers, and gas lasers. The company was founded in 1979 and is headquartered in San Jose, CA.

Lumentum Holdings Inc

Lumentum Holdings is seeing extreme volatility as it undergoes S&P 500 index inclusion, driving a surge of forced institutional buying that has captured significant market attention. The community is sharply divided, with bulls pointing to the company's critical role in AI infrastructure and hyperscaler partnerships, while skeptical traders warn of unsustainable valuations and aggressive short-term price swings.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

The United States Oil Fund is experiencing intense volatility and heavy trading volume as markets closely track heightened geopolitical tensions in the Middle East and ongoing uncertainty surrounding the Strait of Hormuz. Community sentiment is deeply divided, with many traders actively debating whether the current price action represents a speculative bubble fueled by geopolitical headlines or a structural supply shock that could drive oil significantly higher.

Eastman Kodak Co. engages in the provision of analog and digital innovations. It operates through the following segments: Traditional Printing, Digital Printing, Advanced Materials and Chemicals, and Brand. The Traditional Printing segment consists of Prepress Solutions, which includes Kodak's digital offset plate offerings and computer-to-plate imaging solutions. The Digital Printing segment contains Electrophotographic Printing Solutions, Prosper, Versamark and Software. The Advanced Materials and Chemicals segment consists of four lines of business: Industrial Film and Chemicals, Motion Picture, Advanced Materials and Functional Printing, and Kodak Services for Business (KSB). The Brand segment includes licensing of the Kodak brand to third parties. The company was founded by George Eastman in 1880 and is headquartered in Rochester, NY.

Eastman Kodak Co.

Eastman Kodak is trending as investors react to the company's expansion into pharmaceutical manufacturing and the launch of new regulated laboratory products, fueling speculation about potential U.S. government contracts and domestic supply chain partnerships. The community remains focused on the company's improved balance sheet and its strategic pivot toward advanced materials, with active discussions on the long-term potential for a major industrial turnaround.

Solana is a high-performance Layer 1 blockchain designed for mass adoption by providing a fast, secure, and low-cost environment for decentralized applications. It distinguishes itself by scaling globally without the use of complex sharding or multiple layers, instead maintaining a single, unified ledger to avoid liquidity fragmentation. This architecture allows it to process thousands of transactions per second with sub-second finality, often at a cost of less than a penny per transaction.  The network operates on a unique hybrid model that combines Proof of Stake with an innovation called Proof of History, which functions as a decentralized clock to timestamp transactions. This system reduces the need for constant node communication, allowing the Sealevel engine to run non-conflicting smart contracts in parallel across multiple CPU cores. Further efficiency is gained through the Gulf Stream protocol, which reduces confirmation times by forwarding transactions to validators before the current block is finished.  Founded in 2017 by Anatoly Yakovenko, Solana is now supported by the Switzerland-based Solana Foundation and significant institutional investors like Andreessen Horowitz and Polychain Capital. The platform’s native token, SOL, serves as the primary currency for paying transaction fees, participating in network governance, and securing the system through staking.   Solana has also seen significant institutional adoption ranging from spot Solana ETFs to major partnerships including Visa's 2025 launch of USDC settlement on the network and the tokenization of public equity by firms like Galaxy Digital.

Solana

Solana is facing downward pressure amid broader market uncertainty, with community sentiment divided between those aggressively accumulating the dip and others expressing frustration over technical volatility and ecosystem exploits like the recent Drift protocol incident. Investors remain focused on developer momentum and potential institutional adoption as key drivers that could pull the asset out of its current slump.

Tilray Brands, Inc. engages as a consumer packaged goods company, which focuses on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. It operates through the followings segments: Cannabis, Distribution, Beverage, and Wellness. The Cannabis segment focuses on cultivation, production, distribution, and sale of both medical and adult-use cannabis products. The Distribution segment is involved in purchase, resale, and distribution of pharmaceutical and wellness products. The Beverage segment refers to the production, marketing, and sale of beverages. The Wellness segment represents the production, marketing, and distribution of hemp-based food and other wellness products. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Tilray Brands Inc

Tilray Brands is attracting heavy investor attention ahead of its upcoming earnings report, with the community actively debating the company's shift toward a diversified consumer goods strategy and the potential for a significant rally should federal rescheduling news materialize. Despite frustrations over historical share price volatility and management's dilution strategy, bullish sentiment remains tied to improving medical cannabis fundamentals and hopes for a major short squeeze.

Applied Optoelectronics, Inc. engages in the design and manufacture of optical communications products. Its products include optical devices, such as laser diodes, photodiodes, related modules and circuitry, and equipment for applications in fiber-to-the-home, cable television, point to point communications, and wireless. The company was founded by Chih Hsiang Lin on February 28, 1997 and is headquartered in Sugar Land, TX.

Applied Optoelectronics Inc

Applied Optoelectronics is currently surging following the announcement of a new volume order for 800G data center transceivers from a major hyperscale client, fueling intense discussion regarding the company's role in AI infrastructure. While the community is actively debating the stock's parabolic trajectory and potential for further momentum, many traders remain hyper-focused on its high volatility and the ongoing influence of institutional positioning.

Kelly Services, Inc. engages in the provision of talent solutions. It operates through the following segments: Professional and Industrial, Science, Engineering, and Technology, Education, Outsourcing and Consulting, and International. The Professional and Industrial segment includes the provision of administrative, accounting and finance, light industrial, contact center staffing, and other workforce solutions. The Science, Engineering, and Technology segment focuses on staffing, outcome-based, permanent placement services, clinical research, and telecommunications. The Education segment involves offering education and therapy services talent through staffing, permanent placement, and executive search services to Pre-K-12 school districts and organizations. The Outsourcing and Consulting segment consists of global talent supply chain and workforce solutions, including Managed Service Provider (MSP), Recruitment Process Outsourcing (RPO), Payroll Process Outsourcing (PPO), and executive coaching programs. The company was founded by William Russell Kelly on October 7, 1946 and is headquartered in Troy, MI.

Kelly Services, Inc. - Ordinary Shares - Class B

KELYB is seeing intense community activity driven by its extremely low float, which investors believe creates the potential for rapid volatility and short squeezes. Traders are closely monitoring upcoming investor calls and the influence of major institutional positions, with many debating whether the current price action represents a temporary pullback or a setup for further gains.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Promising Biotech Stocks To Keep An Eye On - December 9th

WAVE Life Sciences, Exicure, argenex, Danaher, Senti Biosciences, Abivax, and Vertex Pharmaceuticals are the seven Biotech stocks to watch today, according to MarketBeat's stock screener tool...

<ul class="summary-bullets"><li>Phase 2 data showed rapid increases in CD34+ stem cells, allowing same-day dosing and collection.</li><li>Daratumumab-treated patients, who often struggle with mobilization, also achieved strong collection outcomes.</li><li>The treatment was well tolerated, with no burixafor-related side effects above Grade 2 reported in the study.</li></ul>Shares of Exicure Inc. (XCUR) surged nearly 40% on Tuesday after the company reported encouraging Phase 2 results for its experimental stem cell mobilization drug burixafor (GPC-100).&nbsp;The findings, shared at the American Society of Hematology meeting in Orlando, focused on patients with multiple myeloma preparing for autologous stem cell transplant.<h2 class="st-heading-2">Trial Meets Primary Endpoint</h2>The open-label, multicenter study found that 17 of 19 patients reached the trial’s stem cell collection target within two sessions. Two additional patients reached the target after an extra session.Among participants who proceeded to transplant, median neutrophil engraftment occurred in 13 days and platelet engraftment in 17.5 days. Exicure said burixafor worked quickly, boosting CD34+ stem cells, the cells doctors need to collect for transplant, within about an hour. The company said that the rapid rise makes it possible to give the drug and collect the cells on the same day.<h2 class="st-heading-2">Activity In Daratumumab-Exposed Patients</h2>Sixteen of 19 patients had previously received daratumumab, a therapy linked to reduced stem cell yield. Of these, 14 patients met the primary endpoint, including 12 of 14 who had also been treated with lenalidomide.Longer intervals between the last daratumumab dose and leukapheresis were associated with higher CD34+ cell yields.<h2 class="st-heading-2">Safety Findings</h2>The regimen of burixafor, propranolol, and G-CSF was well tolerated, with no adverse events above Grade 2 attributed to burixafor.“In this Phase 2 study, the combination of burixafor, G-CSF and propranolol showed an excellent safety profile and supported reliable mobilization of hematopoietic progenitor cells,” said lead investigator Jack Khouri of the Cleveland Clinic, adding that rapid cell mobilization may reduce the burden of the process for patients.<h2 class="st-heading-2">Pipeline Expansion Plans</h2>Burixafor, a selective CXCR4 antagonist acquired through Exicure’s January purchase of GPCR Therapeutics’ assets, is also being evaluated in sickle cell disease, rare transplant-eligible disorders, and cell and gene therapy settings.Exicure said a chemosensitization study in acute myeloid leukemia is planned, based on the drug’s ability to mobilize malignant cells from the bone marrow into peripheral blood.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment for Exicure was ‘extremely bullish’ amid ‘extremely high’ message volume. One user said, “Wow! This candle is showing a strong bullish setup. A powerful pump is coming.”<stembedurl>https://stocktwits.com/OmidArefi/message/638609203</stembedurl><figure class="image"><img style="aspect-ratio:968/141;" src="https://news.stocktwits-cdn.com/xcur_ss_png_95a0e0eba0.webp" alt="xcur ss.png" width="968" height="141"><figcaption>XCUR sentiment and message volume as of December 9| Source: Stocktwits</figcaption></figure>Another user called the stock cheap at the current price, “considering the data!”<stembedurl>https://stocktwits.com/Notoriousinvestor/message/638601332</stembedurl><a href="https://stocktwits.com/symbol/XCUR">Exicure’s stock</a> has declined 45% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Exicure’s stock (XCUR) has declined 45% so far in 2025. (Photo credit: Getty Images)

Exicure Stock Soars 40% After Stem Cell Drug Helps Most Patients Hit Phase 2 Goal — Traders Call It ‘Cheap’ At Current Levels

The company's stem cell drug burixafor helped nearly 90% of patients meet the Phase 2 goal.

Equity

Exicure, Inc. Loss At -$2.44 Mln In Q3

(RTTNews) - Exicure, Inc. (XCUR) reported Loss for third quarter of -$2.44 million...

Halper Sadeh LLC Encourages Exicure, Inc. Shareholders to Contact the Firm to Discuss Their Rights

Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Exicure, Inc. (NASDAQ: XCUR) breached their fiduciary duties to shareholders. If you...

Shares of Exicure Inc. surged more than 25% on Thursday, reaching levels last seen over three weeks ago, following the announcement of a strategic acquisition and collaboration deal with South Korea-based GPCR Therapeutics.Exicure revealed it has agreed to purchase all shares of GPCR Therapeutics USA, the California-based subsidiary of GPCR Therapeutics.&nbsp;As part of the agreement, Exicure and GPCR have entered into a licensing and collaboration arrangement to advance and commercialize GPCR-related technologies.While financial terms of the acquisition were not disclosed, Exicure outlined that the deal includes milestone payments to GPCR Therapeutics tied to clinical trial progress, marketing approvals, and net sales achievements.&nbsp;Additionally, Exicure will pay a recurring royalty of at least 10% of net sales derived from the licensed technologies.Retail interest surged after the announcement, with Exicure’s message volume on Stocktwits spiking, placing the ticker among the top 10 trending symbols on the platform.<stembedurl>https://stocktwits.com/topstockalerts/message/601124689</stembedurl><stembedurl>https://stocktwits.com/Pippi_Langstrumpf66/message/601121735</stembedurl>GPCR USA is noted for its work in developing cutting-edge treatments, including Opdivo, a widely used autoimmune disease therapy generating about $10 billion in annual revenue.&nbsp;The company is also behind Yervoy, the first FDA-approved treatment for lung cancer.&nbsp;Currently, GPCR USA is conducting a Phase 2 clinical trial targeting blood cancer patients, focusing on those requiring hematopoietic stem cell transplantation (HSCT) for conditions like multiple myeloma.Exicure’s stock has been a standout performer, gaining 265% over the past 12 months.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Hand holding test tube over stock data on computer monitor. | Image source: Getty Images

Exicure Stock Soars Over 25% On Acquisition Of GPCR Therapeutics’ U.S. Unit: Retail Chatter Spikes 

GPCR USA is noted for its work in developing cutting-edge treatments, including Opdivo, a widely used autoimmune disease therapy generating about $10 billion in annual revenue.

Micro-cap early-stage biotech Exicure, Inc.’s ($XCUR) shares rose sharply in premarket trading on Friday following a deal to acquire a cancer drug pipeline from a South Korean company.The company announcement late Thursday that it had signed a memorandum of understanding with GPCR Therapeutics on Dec. 24 to acquire the latter’s US subsidiary. The agreement also provides for technology transfer and collaborative research on GPCR’s other ongoing drug development pipelines.Chicago-based Exicure said it intends to receive technology transfer for GPCR Therapeutics’ CXCR4 inhibitor, which is in Phase 2 development, along with its related patents and intellectual property.&nbsp;The company views the proposed acquisition as a means to advance as a clinical-stage biotech. It plans to finalize the ongoing clinical trials involving stem cell mobilizers in multiple myeloma patients and prepare clinical studies related to acute myeloid leukemia.&nbsp;Excurire said the market potential for the two blood cancer types is around $1 billion to $2 billion annually.The company also plans to collaborate on R&amp;D in GPCR’s ongoing research in immuno-oncology, fibrosis treatments, and obesity therapies.&nbsp;South Korean drug company GPCR specializes in GPCR (G Protein-Coupled Receptor), representing over one-third of all drug targets. The company has secured target patents around prominent GPCRs such as CXCR4. It possesses multiple pipelines addressing blood cancers and solid tumors, genetic disorders, idiopathic pulmonary fibrosis, and obesity, including ongoing Phase 2 trials in the U.S. for multiple myeloma.&nbsp;Exicure said the deal will be funded from the $14 million capital investments it recently secured in three transactions.&nbsp;In an 8-K filing with the SEC, Exicure said the Nasdaq has notified that the company has met all requirements for continued listing on the exchange.A Stocktwits watcher pointed to the stock's low float and predicted a sharp move on the news.<stembedurl>https://stocktwits.com/SBW_Trades/message/597953319</stembedurl>In premarket trading, Exicure stock was up 8.41% at $18.70 at 7:05 a.m.ET. The stock has gained nearly 500% for the year.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/5-media-and-entertainment-and-communication-services-stocks-that-gained-massive-retail-following-on-stocktwits-in-2024/cJO7BR7RjM">5 Media &amp; Entertainment And Communication Services Stocks That Gained Massive Retail Following On Stocktwits in 2024</a>

Woman examining laboratory samples - stock photo | Image source: Getty Images

Exicure Stock Surges On Blood Cancer Portfolio Acquisition Plans, Nasdaq Compliance: Retail Exuberant

Chicago-based Exicure said it intends to receive technology transfer for GPCR Therapeutics’ CXCR4 inhibitor, along with its related patents and intellectual property. 

Exicure, Inc. develops therapeutics for immuno-oncology, genetic disorders and other indications based on its proprietary Spherical Nucleic Acid. The firm's product pipeline includes Cavrotolimod (AST-008) and XCUR-FXN. The company was founded by Chad A. Mirkin and Colby Shad Thaxton in June 2011 and is headquartered in Redwood City, CA.

XCUR
Exicure Inc

Feed

News

Sentiment

Fundamentals

Info

Latest XCUR News

XCURExicure Inc